REICH, K.; SIMPSON, E. L.; LANGLEY, R.; WARREN, R. B.; COSTANZO, A.; SAEKI, H.; ALMGREN, P.; GJERUM, L.; CARLSSON, A.; GOODERHAM, M.; PINTER, A.; DE BRUIN-WELLER, M.; BLAUVELT, A. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s79, 2022. DOI: 10.25251/skin.6.supp.79. Disponível em: https://dermsquared.com/skin/article/view/1837. Acesso em: 20 sep. 2024.